Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Abbott Labs

Anheuser-Busch InBev

H&R Block

Kroger

NextEra Energy

Procter & Gamble

Sturm, Ruger & Company

Vista Outdoor

No matter who wins the presidential election, the results will be jarring to millions of Americans. Prepare yourself early by getting into these companies to invest in before 2021.

9 Companies to Invest In Before We Hit 2021

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

Inovio Pharmaceuticals

Moderna

The overall stock market sell-off is pulling all three biotech stocks down.

Why Coronavirus Vaccine Stocks Moderna, Novavax, and Inovio Are Sinking Today

Though Novavax stock is looking like the antithesis of its former self in the first half of this year, the wildness detracts from what could be the breakthrough name in the novel coronavirus vaccine race. The post Novavax Stock Might Actually Win This War of Attrition appeared first on InvestorPlace.

Novavax Stock Might Actually Win This War of Attrition

It's too soon to name Novavax the leader in developing a novel coronavirus vaccine. But NVAX stock is worth watching through the end of 2020.

Vaccine Hopeful Novavax Could Be Worth a Shot

The trials could enroll up to 30,000 in the U.S. and Mexico.

Novavax Will Launch U.S. Phase 3 Trials Of Coronavirus Vaccine By End Of November

The biotech gave an encouraging update about its late-stage coronavirus vaccine program.

Why Novavax Stock Is Moving Higher Today

Novavax, Inc. (NASDAQ: NVAX) issued an update Tuesday on a late-stage study of its coronavirus vaccine program, sending its shares higher.  US Late-Stage Study Kicks Off In Late November: Gaithersburg, Maryland-based Novavax said it expects the Phase 3 trial of its coronavirus vaccine candidate NVX-CoV2373 in the U.S. and Mexico to begin by the end of November.

Novavax Rallies On Phase 3 Coronavirus Study Updates, Imminent Phase 2 Readout

Moderna and Novavax announced advances for their respective Covid-19 vaccine candidates, with the U.K. starting a 'rolling review' of Moderna's vaccine and Novavax expanding its key trials. The post Moderna Vaccine Gets U.K. "Rolling Review"; Novavax Expands Trials appeared first on Investor's Business Daily.

Moderna Vaccine Gets U.K. "Rolling Review"; Novavax Expands Trials

Amgen

Vertex Pharmaceuticals

Marketed products -- and work in the pipeline -- should translate into future growth for these shares.

3 Biotech Stocks I'd Buy Right Now

Shares of Novavax Inc. gained 2.9% in trading on Tuesday after the company said it expects to launch a Phase 3 trial for its COVID-19 vaccine candidate in Mexico and the U.S. by the end of next month. It already started a late-stage trial for its vaccine in the U.K. in September.

Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax' nanoparticle technology and includes Novavax' proprietary Matrix‑M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices' (ACIP) meeting.

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

BioNTech SE

Pfizer

Some coronavirus vaccines must be stored at extremely low temperatures. Could this limit their market potential?

Could Some Coronavirus Vaccines Be Left Out in the Cold?

AstraZeneca

CureVac B.V

Johnson & Johnson

The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.

Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact

Will the Coronavirus Vaccine Market Be Winner-Take-All?

What's the Best Way to Invest in Coronavirus Vaccine Stocks?

It's important to look at the big picture.

Are Coronavirus Vaccine Stocks Too Expensive?

The coronavirus vaccine candidates attempt to trick the body in different ways.

What Are the Differences Between the Leading Coronavirus Vaccine Candidates?

Two are huge drugmakers and one is a small biotech with tremendous growth potential.

3 Coronavirus Vaccine Stocks That Especially Stand Out Right Now

NVAX stock may be riding high on AstraZeneca's clinical trial blunder, but the path forward is not smooth for Novavax. Here's why.

Can Novavax Stock Overcome Growing Vaccine Distrust?

Innovative Industrial Properties

Plug Power

There's no guarantee that these stocks will triple this decade, but each of them has a clear path to do so.

3 Stocks That Could Realistically Triple by 2030 or Even Sooner

NVAX stock has to produce the goods before the markets reward it again, as brownie points for gathering funds will only take them so far. The post Coronavirus Hype Is Pushing Novavax to Unrealistic Highs appeared first on InvestorPlace.

Coronavirus Hype Is Pushing Novavax to Unrealistic Highs

NVAX stock may actually rise meaningfully above its current levels, as its coronavirus vaccine could still be very profitable. The post Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Company's COVID-19 vaccine, at the 2020 World Vaccine Congress Europe. The Congress takes place virtually October 19 - 21, 2020.

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

Two programs may seek emergency use authorization within the next six weeks.

News for Novavax Stock (NVAX)